Posted by Michael Wonder on 21 Dec 2023
Ravulizumab for the treatment of patients with AQP4 antibody positive neuromyelitis optica spectrum disorder
20 December 2023 - NICE is unable to make a recommendation on the use of ravulizumab (Ultomiris) for the treatment of adults with AQP4 antibody positive neuromyelitis optica spectrum disorder because Alexion Pharmaceuticals withdrew its evidence submission.
NICE will review this decision if Alexion Pharmaceuticals decides to make a submission.
